The coronavirus (CoV) that causes severe acute respiratory syndrome, or SARS, is called SARS-CoV. CoVs, which are enveloped viruses with positive-sense, single-stranded RNA and can target the human respiratory system to spread disease, include not only the SARS virus but also MERS and SARS-CoV-2, which is the source of COVID-19.
The spike (S), membrane (M), envelope (E), and nucleocapsid (N) proteins are the four main structural proteins of CoVs. By binding to a cellular receptor (ACE2 for SARS-CoV and SARS-CoV-2, DPP4 for MERS-CoV), an S protein mediates the CoV entry into host cells, which is followed by the fusion of the virus and host cell membranes. Following entry, a large number of nonstructural proteins, including Mpro (main protease or 3CLpro), PLpro (papain-like protease), and RdRp (RNA-dependent RNA polymerase), participate in genome replication and subgenomic RNA transcription.The structural proteins are then translated, put together into mature virions, and exocytosed to release them via vesicles. It is noteworthy that a protease known as TMPRSS2 (transmembrane protease, serine 2), which cleaves S protein, plays crucial roles throughout the entire life of CoVs (such as attachment, assembling, and release). For the treatment of diseases brought on by CoVs, all the proteins and subcellular structures involved in the life cycle of CoVs are promising targets.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V78704 | CDK9-IN-25 | CDK9-IN-25 (compound 4a) is an imidazopyrazine CDK9 inhibitor (IC50= 0.24 μM). | |
|
V96913 | CDK9-IN-34 | 252725-86-3 | CDK9-IN-34 (Compound 1b) is an inhibitor of CDK9 with IC50 of 0.25 μM. |
|
V101482 | CET-1 | CET-1 is an antiviral drug that inhibits SARS-CoV-2. | |
|
V78762 | Chloroquine-d4 phosphate (Chloroquine-d4 phosphate) | Chloroquine-d4 (phosphate) is the deuterated form of Chloroquine phosphate. | |
|
V54035 | Chloroquine-d5 (chloroquine d5) | 1854126-41-2 | Chloroquine-d5 is the deuterium labelled form of Chloroquine. |
|
V53059 | Cichoriin | 531-58-8 | Cichoriin has obvious activity against SARS-CoV-2 and may become a potential candidate substance for studying severe COVID-19. |
|
V101669 | Cinanserin | 1166-34-3 | Cinnamethiamine (SQ 10643) is a potent and selective 5-HT2 antagonist with Ki values of 41 and 3500 nM for 5-HT2 and 5-HT1, respectively. |
|
V52242 | Cleistanthin B (Diphyllin O-glucoside) | 30021-77-3 | Cleistanthin B (Diphyllin O-glucoside) is an orally bioactive arylnaphthylinolide glycoside. |
|
V76090 | CMX990 | 2882934-64-5 | CMX990 is a SARS-CoV-2 3CL protease inhibitor. |
|
V54435 | Cnicin | 24394-09-0 | Cnicin is a sesquiterpene lactone. |
|
V76076 | Coronastat (NK01-63) | 2922281-15-8 | Coronastat is a potent inhibitor of the SARS-CoV-2 3CL protease. |
|
V84453 | Covidcil-19 | 1225177-95-6 | |
|
V76094 | Crexavibart (BMS-986413; C-144-LS) | 2599039-61-7 | Crexavibart (BMS-986413; C-144-LS) is an IgG1λ2 antibody targeting the SARS-CoV2 spike (S) glycoprotein receptor binding domain. |
|
V86311 | CTSL/B-IN-1 | ||
|
V78997 | D-4-77 | D-4-77 is a potent inhibitor of SARS-CoV-2 Mpro with IC50 of 0.95 μM. | |
|
V76088 | D1N52 | 2894770-48-8 | D1N52 is a potent SARS-CoV-2 3CLpro inhibitor (antagonist) with IC50 of 0.53 μM. |
|
V76078 | D1N8 | 2894770-40-0 | D1N8 is a potent SARS-CoV-2 3CLpro inhibitor (antagonist) with IC50 and CC50 values of 0.44 μM and >20 μM, respectively. |
|
V54437 | Debrisoquin (Debrisoquine; Isocaramidine; Ro 5-3307/1) | 1131-64-2 | Debrisoquin (Isocaramidine) is a TMPRSS2 inhibitor that can suppress SARS-CoV-2 entry into human lung cell lines in a TMPRSS2-dependent manner with IC50 of 22 μM. |
|
V52800 | Dexamethasone-d5 (Hexadecadrol-d5; Prednisolone F-d5) | 358731-91-6 | Dexamethasone-d5 is the deuterated form of Dexamethasone. |
|
V79136 | Dihydromaniwamycin E | 3033567-35-7 | Dihydromaniwamycin E is a heat shock metabolite with anti-viral effect against influenza and SARS-CoV-2 viruses. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
